Abstract

BackgroundFeline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide. Its characteristically high mutation rate leads to escape from the humoral immune response induced by natural infection and/or vaccination and consequently vaccines are not always effective against field isolates. Thus, there is a need to continuously investigate the ability of FCV vaccine strain-induced antibodies to neutralize field isolates.MethodsSeventy-eight field isolates of FCV isolated during the years 2008–2012 from Swedish cats displaying clinical signs of upper respiratory tract disease were examined in this study. The field isolates were tested for cross-neutralization using a panel of eight anti-sera raised in four pairs of cats following infection with four vaccine strains (F9, 255, G1 and 431).ResultsThe anti-sera raised against F9 and 255 neutralised 20.5 and 11.5 %, and 47.4 and 64.1 % of field isolates tested, respectively. The anti-sera against the more recently introduced vaccine strains G1 and 431 neutralized 33.3 and 70.5 % and 69.2 and 89.7 %, respectively. Dual vaccine strains displayed a higher cross-neutralization.ConclusionsThis study confirms previous observations that more recently introduced vaccine strains induce antibodies with a higher neutralizing capacity compared to vaccine strains that have been used extensively over a long period of time. This study also suggests that dual FCV vaccine strains might neutralize more field isolates compared to single vaccine strains. Vaccine strains should ideally be selected based on updated knowledge on the antigenic properties of field isolates in the local setting, and there is thus a need for continuously studying the evolution of FCV together with the neutralizing capacity of vaccine strain induced antibodies against field isolates at a national and/or regional level.Electronic supplementary materialThe online version of this article (doi:10.1186/s13028-015-0178-z) contains supplementary material, which is available to authorized users.

Highlights

  • Feline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide

  • Virus neutralization of FCV field isolates The FCV field isolates were analysed in a neutralization test using eight antisera raised against four commercially available FCV vaccine strains (G1, 431, 255 and F9)

  • The paired anti-sera raised against vaccine strains 255 and F9, which have been used in vaccines for several decades, neutralized 47.4 and 64.1 % or 20.5 and 11.5 % of the field isolates with titres ≥5 (Table 1)

Read more

Summary

Introduction

Feline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide. Its characteristically high mutation rate leads to escape from the humoral immune response induced by natural infection and/or vaccination and vaccines are not always effective against field isolates. Feline calicivirus (FCV) is one of the primary causes of infectious upper respiratory tract disease in cats, an important disease worldwide [1]. Feline calicivirus is a single-stranded RNA-virus of positive sense genome with a high genetic and antigenic variability [4,5,6], associated with escape from the humoral immune response induced by natural infection and/or vaccination. FCV is distributed world-wide in the cat population and is estimated to be the etiological cause of upper respiratory tract disease in 10–50 % of cases [1].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call